Andrea M Austin1, Nirav S Kapadia2,3,4, Gabriel A Brooks2,3,4, Tracy L Onega2,4, A Heather Eliassen5,6, Rulla M Tamimi5,6, Michelle Holmes6, Qianfei Wang2, Francine Grodstein5,6, Anna N A Tosteson2,3,4. 1. The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth, Hanover, NH, USA. andrea.m.austin@dartmouth.edu. 2. The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 3. Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 4. Norris Cotton Cancer Center, Lebanon, NH, USA. 5. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 6. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Abstract
PURPOSE: Increasingly epidemiological cohorts are being linked to claims data to provide rich data for healthcare research. These cohorts tend to be different than the general United States (US) population. We will analyze healthcare utilization of Nurses' Health Study (NHS) participants to determine if studies of newly diagnosed incident early-stage breast cancer can be generalized to the broader US Medicare population. METHODS: Analytic cohorts of fee-for-service NHS-Medicare-linked participants and a 1:13 propensity-matched SEER-Medicare cohort (SEER) with incident breast cancer in the years 2007-2011 were considered. Screening leading to, treatment-related, and general utilization in the year following early-stage breast cancer diagnosis were determined using Medicare claims data. RESULTS: After propensity matching, NHS and SEER were statistically balanced on all demographics. NHS and SEER had statistically similar rates of treatments including chemotherapy, breast-conserving surgery, mastectomy, and overall radiation use. Rates of general utilization include those related to hospitalizations, total visits, and emergency department visits were also balanced between the two groups. Total spending in the year following diagnosis were statistically equivalent for NHS and SEER ($36,180 vs. $35,399, p = 0.70). CONCLUSIONS: NHS and the general female population had comparable treatment and utilization patterns following diagnosis of early-stage incident breast cancers with the exception of type of radiation therapy received. This study provides support for the larger value of population-based cohorts in research on healthcare costs and utilization in breast cancer.
PURPOSE: Increasingly epidemiological cohorts are being linked to claims data to provide rich data for healthcare research. These cohorts tend to be different than the general United States (US) population. We will analyze healthcare utilization of Nurses' Health Study (NHS) participants to determine if studies of newly diagnosed incident early-stage breast cancer can be generalized to the broader US Medicare population. METHODS: Analytic cohorts of fee-for-service NHS-Medicare-linked participants and a 1:13 propensity-matched SEER-Medicare cohort (SEER) with incident breast cancer in the years 2007-2011 were considered. Screening leading to, treatment-related, and general utilization in the year following early-stage breast cancer diagnosis were determined using Medicare claims data. RESULTS: After propensity matching, NHS and SEER were statistically balanced on all demographics. NHS and SEER had statistically similar rates of treatments including chemotherapy, breast-conserving surgery, mastectomy, and overall radiation use. Rates of general utilization include those related to hospitalizations, total visits, and emergency department visits were also balanced between the two groups. Total spending in the year following diagnosis were statistically equivalent for NHS and SEER ($36,180 vs. $35,399, p = 0.70). CONCLUSIONS:NHS and the general female population had comparable treatment and utilization patterns following diagnosis of early-stage incident breast cancers with the exception of type of radiation therapy received. This study provides support for the larger value of population-based cohorts in research on healthcare costs and utilization in breast cancer.
Entities:
Keywords:
Breast cancer; Epidemiology; Generalizability study; Nurses’ Health Study
Authors: David J Hunter; Peter Kraft; Kevin B Jacobs; David G Cox; Meredith Yeager; Susan E Hankinson; Sholom Wacholder; Zhaoming Wang; Robert Welch; Amy Hutchinson; Junwen Wang; Kai Yu; Nilanjan Chatterjee; Nick Orr; Walter C Willett; Graham A Colditz; Regina G Ziegler; Christine D Berg; Saundra S Buys; Catherine A McCarty; Heather Spencer Feigelson; Eugenia E Calle; Michael J Thun; Richard B Hayes; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert N Hoover; Gilles Thomas; Stephen J Chanock Journal: Nat Genet Date: 2007-05-27 Impact factor: 38.330
Authors: A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Donna Spiegelman; Robert L Barbieri; Mitch Dowsett; Susan E Hankinson Journal: J Natl Cancer Inst Date: 2006-10-04 Impact factor: 13.506
Authors: Z Huang; W C Willett; G A Colditz; D J Hunter; J E Manson; B Rosner; F E Speizer; S E Hankinson Journal: Am J Epidemiol Date: 1999-12-15 Impact factor: 4.897
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797